NEWS RELEASE

Biosensors Receives CE Mark Approval for its BioMatrix®

Drug-Eluting Coronary Stent System

Singapore, 18 January 2008 ?

?Company? or ?Biosensors?), today announced that the Company has received

Conformite Europeenne (?CE?) Mark approval for its BioMatrix® drug-eluting stent

system, enabling commercialization of this product in the European Union and the

countries in Asia and Latin America that recognize the CE Mark. The BioMatrix drugeluting

stent system, developed internally by the Company, consists of a unique drugeluting

stent that incorporates a biodegradable polymer and the Company?s proprietary

drug, Biolimus A9®, which inhibits restenosis, or re-narrowing of the arteries, following

stent implantation.

Terumo Corporation (?Terumo?), a licensee of Biosensors? BioMatrix technology, also

announced CE Mark approval for its NOBORI? drug-eluting stent system. In October

2003, Biosensors and Terumo entered into a licensing agreement that granted Terumo

the rights to sell the NOBORI drug-eluting stent system exclusively in Japan and nonexclusively

in countries outside Japan excluding the United States. Under this

agreement, Terumo will share a portion of the revenues from the sales of NOBORI with

Biosensors. In May 2007, Terumo commenced the clinical trial of the NOBORI drugeluting

stent system required for Japanese regulatory approvals.

?We are very pleased to have received CE Mark approval for our BioMatrix stent and

will immediately implement our strategy to make this product available in the approved

markets. Our growth potential in these markets is very strong, as BioMatrix and NOBORI

will be the only drug-eluting stents currently available which incorporate a

biodegradable polymer coating together with an immunosuppressive drug. Positive

clinical data position the BioMatrix stent system to be a potential break-through

product for patients and physicians,? stated Mr. Yoh-Chie Lu, Chairman and Chief

Executive Officer.

Professor Eberhard Grube, Chief of Angiology and Cardiology at Siegburg Heart Center in

Germany and a principal investigator for the BioMatrix clinical trial program

commented, ?BioMatrix will provide a valuable alternative to the drug-eluting stents

currently available to interventional cardiologists. The results from the BioMatrix clinical

trials have been consistently very positive and promising. The three-year follow-up data

released at the Transcatheter Cardiovascular Therapeutics Conference last year

continued to demonstrate BioMatrix?s superior results in terms of safety and clinical

effectiveness. The BioMatrix drug eluting stent has shown excellent procedural

performance and outcome characteristics.?

Mr. Lu added, ?We are also pleased with the timing of this approval, as the increasing

complexity of worldwide regulatory requirements will make it even more difficult to

introduce new technologies into the marketplace. We plan to commence a staged

launch of BioMatrix commencing 1 April 2008. The initial stage will be to introduce

BioMatrix through our existing distribution channels. We will expand these channels to

increase geographical coverage during the first half of our fiscal year beginning in April,

2008 and plan a significant ramp up in sales over the second half of our fiscal year.?

?Many years of effort devoted to developing the BioMatrix drug-eluting stent system

have been validated by this approval. We would like to take this opportunity to

recognize the contributions of our people and the collaborative efforts of our licensees,

especially Terumo Corporation, in achieving this milestone. This is truly an historic day

for Biosensors,? concluded Mr. LuBiosensors International Group, Ltd. (Bloomberg: BIG SP,

## End of Release ##

Media & Investor Relations

Singapore

Mr. Loh Chee Mun

Senior Vice President

Tel: (65) 62135708

Email: cm.loh@biosensors.com

United States

Allen&Caron Inc.

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: matt@allencaron.com

About BioMatrix

BioMatrix offers the unique combination of an innovative anti-restenosic drug, Biolimus

A9

Biolimus A9 was designed specifically to maximize stent efficacy. In addition to effective

immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic

and hydrophobic profile than other drugs in its class, enabling the drug to be rapidly

absorbed into tissue, with reduced systemic exposure.

The PLA polymer fully degrades into water and carbon dioxide as the drug is released,

ultimately leaving in place a biocompatible stent surface. The polymer is coated onto

the outer (abluminal) side of the stent only, enabling the drug to be released to targeted

tissue. The internally-developed stent used in the BioMatrix system is designed for

increased flexibility in delivery.®, a biodegradable polymer, and advanced stent design.

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in

interventional cardiology and critical care procedures. Biosensors is well-positioned to

emerge as a leader in drug-eluting stents and has developed a pipeline of nextgeneration

products that are set to gain market share from traditional therapies such as

conventional Drug Eluting Stent, bare-metal stents and open-heart surgery. Biosensors

has internally developed technology to address each components of a drug-eluting stent

system, including a stent, a stent delivery catheter, a biodegradable polymer and a

proprietary anti-restenosis drug. It has three separate drug-eluting stent programs,

BioMatrix

has licensed aspects of its drug-eluting stent technology to four companies.®, Axxion?, and BioMatrix® Freedom?, a polymer-free drug-eluting stent, and

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the

U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements

generally can be identified by the use of forward-looking terminology, such as ?may,?

?will,? ?expect,? ?intend,? ?estimate,? ?anticipate,? ?believe,? ?project? or ?continue? or

the negative thereof or other similar words. All forward-looking statements involve risks

and uncertainties, including, but not limited to, customer acceptance and market share

gains, competition from companies that have greater financial resources; introduction of

new products into the marketplace by competitors; successful product development;

dependence on significant customers; the ability to recruit and retain quality employees

as Biosensors grows; and economic and political conditions globally. Actual results may

differ materially from those discussed in, or implied by, the forward-looking statements.

The forward-looking statements speak only as of the date of this release and Biosensors

assumes no duty to update them to reflect new, changing or unanticipated events or

circumstances.